培美替尼适应症及禁忌症有哪些药

Pemetinib is a new type of targeted anti-cancer drug. The drug is indicated for patients with locally advanced or metastatic cholangiocarcinoma. It is the world's first targeted therapeutic agent for cholangiocarcinoma. It was developed by Incyte. It has received accelerated approval from the US Food and Drug Administration (FDA) in April 2020. In April 2022, pemetinib was approved for marketing by the National Medical Products Administration (NMPA) of China. The indications are adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have received at least one systemic treatment in the past and have been confirmed to have FGFR2 fusion or rearrangement.

Pemetinib is effective in treating cholangiocarcinoma, but it also has contraindications and precautions. People who are allergic to pemetinib should use it with caution. In addition, you should pay attention to the following points during medication.

Pemetinib can cause RPED, which may cause symptoms such as blurred vision, visual floaters, or light hallucinations. Obtain a comprehensive ophthalmic examination, including OCT, before starting pemetinib, every 6 months for the first 2 months, and every 3 months thereafter during treatment. For episodes of visual symptoms, patients were urgently referred for ophthalmic evaluation and followed every 3 weeks until pemetinib was discontinued or discontinued.

Monitor for hyperphosphatemia and initiate a low-phosphate diet when serum phosphate levels are >5.5 mg/dL. For serum phosphate levels >7 mg/dL, depending on the duration and severity of hyperphosphatemia, initiate phosphate-lowering therapy and discontinue, reduce the dose, or permanently discontinue pemetinib.

Inform pregnant women of potential risks to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 1 week after the last dose. Advise men who are partners of a female of reproductive potential to use effective contraception during treatment with pemetinib and for 1 week after the last dose.

Breastfeeding women should not breastfeed while taking pemetinib and for 1 week after the last dose.

The above are part of the indications and contraindications of pemetinib. For more details, please read the drug instructions. It is recommended that patients take medication as directed by their doctor and receive symptomatic treatment.

Recommended related articles: